Technical Analysis for MACK - Merrimack Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade B 6.55 -0.30% -0.02
MACK closed down 0.3 percent on Friday, August 16, 2019, on 25 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Down
See historical MACK trend table...

Date Alert Name Type % Chg
1,2,3 Pullback Bullish Bullish Swing Setup 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Outside Day Range Expansion 0.00%
Wide Bands Range Expansion 0.00%
1,2,3 Pullback Bullish Bullish Swing Setup -0.30%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -0.30%
Narrow Range Bar Range Contraction -0.30%
NR7 Range Contraction -0.30%
Inside Day Range Contraction -0.30%
Wide Bands Range Expansion -0.30%

Older signals for MACK ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Merrimack Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and preparing to commercialize medicines paired with companion diagnostics for the treatment of cancer in the United States. The company uses its Network Biology proprietary systems biology-based approach to biomedical research. Its therapeutic oncology candidates in clinical development include MM-398, a stable nanotherapeutic encapsulation of the marketed chemotherapy drug irinotecan, which is in multiple ongoing Phase I, Phase II, Phase III clinical trials for various cancers; MM-121, a fully human monoclonal antibody that targets ErbB3, a cell surface receptor implicated in cancer, which is in multiple ongoing Phase I and Phase II clinical trials; and MM-111, a bispecific antibody designed to inhibit ErbB3 signaling in cancer cells that are characterized by overexpression of the ErbB2 cell receptor, which is in multiple ongoing Phase I and Phase II clinical trials. The company's product candidates also include MM-302, a nanotherapeutic encapsulation of doxorubicin with attached antibodies that target the ErbB2 (HER2) receptor in Phase 1 clinical trial in patients with advanced ErbB2 positive breast cancer; MM-151, an oligoclonal therapeutic consisting of a mixture of three human antibody antagonists, which is in Phase I clinical trial; and MM-141, a human tetravalent bispecific antibody designed to inhibit signaling of the PI3K/AKT/mTOR pathway initiated by the insulin-like growth factor 1 receptor(IGF-1R) and ErbB3, which is in Phase 1 clinical trial. It has collaboration and license agreements with Sanofi; Dyax Corp.; PharmaEngine, Inc.; Adimab LLC; University of California; U.S. Public Health Service; and Selexis SA. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.
Medicine Biopharmaceutical Cancer Treatment Of Cancer Antibodies Cancers Chemotherapy Tyrosine Kinase Receptors Epidermal Growth Factor Receptor Her2/Neu University Of California Erb B3 Mm 151
Is MACK a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 7.5
52 Week Low 3.34
Average Volume 53,867
200-Day Moving Average 5.5967
50-Day Moving Average 5.9369
20-Day Moving Average 6.2855
10-Day Moving Average 6.62
Average True Range 0.277
ADX 32.63
+DI 24.5545
-DI 14.1767
Chandelier Exit (Long, 3 ATRs ) 6.149
Chandelier Exit (Short, 3 ATRs ) 6.061
Upper Bollinger Band 7.2388
Lower Bollinger Band 5.3322
Percent B (%b) 0.64
BandWidth 30.333307
MACD Line 0.2325
MACD Signal Line 0.2224
MACD Histogram 0.0101
Fundamentals Value
Market Cap 86.98 Million
Num Shares 13.3 Million
EPS 32.12
Price-to-Earnings (P/E) Ratio 0.20
Price-to-Sales 1.06
Price-to-Book 1.44
PEG Ratio 0.06
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 6.78
Resistance 3 (R3) 6.78 6.71 6.74
Resistance 2 (R2) 6.71 6.65 6.71 6.72
Resistance 1 (R1) 6.63 6.62 6.60 6.63 6.71
Pivot Point 6.56 6.56 6.54 6.56 6.56
Support 1 (S1) 6.48 6.50 6.45 6.48 6.39
Support 2 (S2) 6.41 6.47 6.41 6.38
Support 3 (S3) 6.33 6.41 6.36
Support 4 (S4) 6.33